N/A N=230 Cervical Ripening in Premature Rupture of Membranes
Pregnancy · Premature Rupture of Membranes · Preterm Premature Rupture of Membranes
Primary: Rate of Cesarean Section — 27; 26; 89; 86 participants — p=0.99
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=19 The Adverse Drug Reaction (ADRe) Profile for Polypharmacy
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
N/A N=254 Efficacy of 3 Regimens of Chloroquine and Primaquine for Treatment of P. Vivax Malaria, Cruzeiro do Sul, Acre, Brazil
P Vivax · Malaria, Vivax
Primary: Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled — 61; 88; 90 participants
Phase 3 N=385 Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
Prostate Cancer
Primary: Specificity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer…
Phase 3 N=741 Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults
Migraine
Primary: Change From Baseline in the Mean Number of Total Migraine Days Per Month in the Last 4 Weeks of the DBT Phase — -4.3; -3.5 Total Migraine Days per Month — p=0.0099
Phase 2 N=6 Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B
Hemophilia B
Primary: Number of Subjects Who Achieved FIX Level ≥12% — 3; 4; 4; 4 Participants
N/A N=197 Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Urinary Incontinence · Prostate Cancer
Primary: Time to Continence — NA; NA weeks — p=0.22
N/A N=32 A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World
Leukemia, Myeloid, Acute
Primary: Real-World Event-Free Survival (rwEFS) — 1.66 months
Phase 2 N=52 Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy
Pancreas Cancer · Pancreas Disease · Pancreas Adenocarcinoma
Primary: Number of Participants With a Clinically Significant Post-operative Pancreatic Fistula (POPF) — 13 Participants
N/A N=115 Effects of Yoga and Meditation on The Birth Process
Birth, First · Labor Pain · State Anxiety
Primary: Characteristics of Labor (Pregnant) — 30; 59; 30; 59 participants
Phase 2 N=30 Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)
Multiple Myeloma
Primary: Relative Dose Intensity (RDI) Per Cohort — 97.9; 89.6 percentage of dose
Phase 3 N=74 Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
Squamous Cell Carcinoma of the Head and Neck
Primary: Number of Participants With an Adverse Event (AE) — 12; 10; 27; 24 Participants
Phase 1 N=21 A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
Advanced or Unresectable Melanoma Progressing After PD1 Blockade
Primary: Incidence of Treatment-emergent Adverse Events Including Treatment-emergent Serious Adverse Events Assessed by Common Terminology Criteria for Adverse Events (CTCAE)…
Phase 3 N=33 Ketamine for Treatment Resistant Late-Life Depression
Treatment Resistant Depressive Disorder
Primary: Percentage of Participants Demonstrating at Least a 50% Reduction on Montgomery-Asberg Depression Rating Scale Scores — 0; 2; 8; 6 Participants
N/A N=24 The Effect of Video Game Exercise on Dynamic Balance and Gait in Individuals With Huntington's Disease
Huntington's Disease
Primary: Gait Parameters — 1.289; 1.292 meters per second